Nasdaq
華爾街日報Eurofins Scientific (ENXTPA:ERF) Valuation Check After Muted Returns And Efficiency Investment Plans
Eurofins Scientific (ENXTPA:ERF) is back in focus after recent share price moves, with investors weighing its €7,144.3m revenue base and €380.9m net income against mixed short term and multi year total returns.
See our latest analysis for Eurofins Scientific.
Recent trading has been fairly muted, with a 1 month share price return of 5.41% but a 3 year total shareholder return decline of 6.69% and a 5 year total shareholder return decline of 10.72%, suggesting longer term momentum has been fading even as shorter term interest has picked up.
If Eurofins Scientific has you rethinking your exposure to healthcare and diagnostics, it could be a good moment to broaden your watchlist across healthcare stocks.
With €7,144.3m in revenue, €380.9m in net income and an intrinsic value estimate suggesting a roughly 41% discount, is Eurofins Scientific quietly undervalued, or is the market already pricing in all the future growth?
Most Popular Narrative: 3% Undervalued
With Eurofins Scientific last closing at €62.00, the most followed narrative pegs fair value slightly higher at about €63.93, suggesting a small valuation gap that hinges on medium term earnings expectations.
The company's significant investments in automation, digitalization, and its hub-and-spoke laboratory infrastructure are expected to materially improve operating efficiency and scalability by 2027. These measures should drive enhanced net margins and earnings growth as operational costs decrease and productivity improves.
Curious what sits behind that modest gap to fair value? The narrative leans heavily on higher margins, faster top line growth, and a lower future earnings multiple. The full set of projected revenues, profits, and discount rate assumptions is what really moves the needle here.
Result: Fair Value of €63.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on biopharma and genomics stabilising, as well as acquisitions like SYNLAB Spain being integrated without prolonged margin drag or heavier than expected restructuring costs.
Find out about the key risks to this Eurofins Scientific narrative.
Build Your Own Eurofins Scientific Narrative
If you see the assumptions differently or want to stress test your own view of Eurofins Scientific, you can build a personalised scenario in just a few minutes, starting with Do it your way.
A great starting point for your Eurofins Scientific research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
Looking for more investment ideas?
If Eurofins Scientific is already on your radar, it is worth broadening your search so you are not relying on a single story or sector.
- Pinpoint potential value opportunities by scanning these 870 undervalued stocks based on cash flows that may offer attractive prices relative to their underlying cash flows.
- Ride powerful tech trends by tracking these 25 AI penny stocks that are tied to artificial intelligence themes across different parts of the market.
- Target dependable income by filtering for these 14 dividend stocks with yields > 3% that can help you focus on yields above 3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com